



You are invited to a presentation on NUPLAZID[®]:

The First and Only FDA-Approved Treatment for Delusions and Hallucinations Associated With Parkinson's Disease Psychosis

Presented by

Fay H. Bemby, NP

Lecturer

Department of Psych Mental Health
University of Tennessee Knoxville
Knoxville, TN

Meeting Details

Thursday, April 25, 2019 | 6:30 PM

Bonefish Grill

1902 N Roan Street
Johnson City, TN 37601
423-434-0247

Attendees will have the option to accept the Acadia-provided food and beverage service, opt out of all food and beverage, or purchase their own food and beverage.

There is no cost to attend this meeting.

Program Objectives

- Discuss educational information about Parkinson's disease psychosis, including:
 - What is Parkinson's disease psychosis?
 - Why does Parkinson's disease psychosis matter?
 - Why is targeting serotonin of therapeutic value for Parkinson's disease psychosis?
- Review clinical efficacy data and safety profile of NUPLAZID[®] (pimavanserin) 34 mg, the first and only FDA-approved treatment for delusions and hallucinations associated with Parkinson's disease psychosis

Seating is limited, so register now.

Enter 300061 at

<https://ACADIAPrograms.com>.

Online registration is preferred.

You may also contact

Michael Alm

at 865-850-6308 or

email malm@acadia-pharm.com.

Please note: This program is subject to cancellation.

Indication

NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Important Safety Information for NUPLAZID (pimavanserin)

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
- NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis.

Please see additional Important Safety Information on next page.

Important Safety Information for NUPLAZID (pimavanserin) (Cont'd)

Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.

QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

Adverse Reactions: The most common adverse reactions ($\geq 2\%$ for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs $<1\%$).

Drug Interactions: Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily. Coadministration with strong CYP3A4 inducers may reduce NUPLAZID exposure. Monitor patients for reduced efficacy and an increase in NUPLAZID dosage may be needed.

Pediatric Use: Safety and efficacy have not been established in pediatric patients.

Dosage and Administration

Recommended dose: 34 mg taken orally once daily, without titration.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

Indication

NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Please see accompanying full Prescribing Information, also available at www.NUPLAZIDhcp.com.

ACADIA Pharmaceuticals is pleased to sponsor this program to provide information consistent with industry guidelines. This program is not an accredited CME program and is not designed to meet any training and/or educational requirements. In accordance with the PhRMA Code on Interactions With Health Care Professionals, attendance at this educational program is limited to only Health Care Professionals (Physicians, Nurse Practitioners, Physician Assistants, RNs, Clinical Pharmacists, Social Workers). Accordingly, attendance by guests or spouse is not permitted.

To comply with certain federal, state, and local laws that prohibit or limit the provision of meals to health care professionals and/or state employees, ACADIA Pharmaceuticals does not offer a complimentary meal to individuals who are subject to such restrictions. Attendees to whom such restrictions apply should not avail themselves of the complimentary meal. Please note that ACADIA Pharmaceuticals is required to report the value of a provided meal pursuant to applicable federal and state laws.

This invitation is non-transferrable.